Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products for the treatment of rare diseases. Orbus is committed to bringing innovative products to severely underserved patients with rare diseases. They focus passionately on delivering more positive outcomes for patients facing life-threatening or severely life-altering conditions. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.